EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

Daphne S Bakker; Lieneke F M Ariens; Barbara Giovannone; DirkJan Hijnen; Eveline M Delemarre; Edward Knol; Stefan Nierkens; Marjolein S de Bruin-Weller; Judith L Thijs; Julia Drylewicz

doi:10.1111/all.14492

EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

Daphne S Bakker, Lieneke F M Ariens, Barbara Giovannone, DirkJan Hijnen, Eveline M Delemarre, Edward Knol, Stefan Nierkens, Marjolein S de Bruin-Weller, Judith L Thijs, Julia Drylewicz

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

3 Downloads (Pure)

Original language	English
Pages (from-to)	3287-3289
Number of pages	3
Journal	Allergy
Volume	75
Issue number	12
DOIs	https://doi.org/10.1111/all.14492
Publication status	Published - Dec 2020

Keywords

atopic dermatitis
biologics
biomarkers

Access to Document

10.1111/all.14492Licence: CC BY-NC-ND

all.14492Final published version, 383 KBLicence: CC BY-NC-ND

Cite this

@article{5c85b59a12f6447ebfd5ef877b8a8c46,

title = "EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers",

keywords = "atopic dermatitis, biologics, biomarkers",

author = "Bakker, {Daphne S} and Ariens, {Lieneke F M} and Barbara Giovannone and DirkJan Hijnen and Delemarre, {Eveline M} and Edward Knol and Stefan Nierkens and {de Bruin-Weller}, {Marjolein S} and Thijs, {Judith L} and Julia Drylewicz",

note = "Funding Information: Dr Bakker reports personal fees from Sanofi Genzyme, outside the submitted work. Dr Hijnen reports grants and personal fees from AbbVie, personal fees from Eli Lilly, personal fees from Incyte, personal fees from Sanofi/Genzyme, grants from Thermo Fisher and personal fees from Pfizer, outside the submitted work. Dr de Bruin‐Weller reports grants as Advisory Board Member/consultant AbbVie, grants as Advisory Board Member/consultant Pfizer, grants as Advisory Board Member/consultant Sanofi Genzyme, grants as Advisory Board Member UCB, grants as Advisory Board Member/consultant Eli Lilly, grants as Advisory Board Member/consultant Regeneron, grants as Advisory Board Member Galderma, grants as PI multicenter studies AbbVie, grants as PI multicenter studies Pfizer, grants as PI multicenter studies Galderma, outside the submitted work. Dr Thijs reports personal fees from Sanofi Genzyme, outside the submitted work. All other authors have nothing to disclose.",

year = "2020",

month = dec,

doi = "10.1111/all.14492",

language = "English",

volume = "75",

pages = "3287--3289",

journal = "Allergy",

issn = "0105-4538",

publisher = "Wiley-Blackwell",

number = "12",

}

TY - JOUR

T1 - EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

AU - Bakker, Daphne S

AU - Ariens, Lieneke F M

AU - Giovannone, Barbara

AU - Hijnen, DirkJan

AU - Delemarre, Eveline M

AU - Knol, Edward

AU - Nierkens, Stefan

AU - de Bruin-Weller, Marjolein S

AU - Thijs, Judith L

AU - Drylewicz, Julia

N1 - Funding Information: Dr Bakker reports personal fees from Sanofi Genzyme, outside the submitted work. Dr Hijnen reports grants and personal fees from AbbVie, personal fees from Eli Lilly, personal fees from Incyte, personal fees from Sanofi/Genzyme, grants from Thermo Fisher and personal fees from Pfizer, outside the submitted work. Dr de Bruin‐Weller reports grants as Advisory Board Member/consultant AbbVie, grants as Advisory Board Member/consultant Pfizer, grants as Advisory Board Member/consultant Sanofi Genzyme, grants as Advisory Board Member UCB, grants as Advisory Board Member/consultant Eli Lilly, grants as Advisory Board Member/consultant Regeneron, grants as Advisory Board Member Galderma, grants as PI multicenter studies AbbVie, grants as PI multicenter studies Pfizer, grants as PI multicenter studies Galderma, outside the submitted work. Dr Thijs reports personal fees from Sanofi Genzyme, outside the submitted work. All other authors have nothing to disclose.

PY - 2020/12

Y1 - 2020/12

KW - atopic dermatitis

KW - biologics

KW - biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85088387626&partnerID=8YFLogxK

U2 - 10.1111/all.14492

DO - 10.1111/all.14492

M3 - Comment/Letter to the editor

C2 - 33305359

SN - 0105-4538

VL - 75

SP - 3287

EP - 3289

JO - Allergy

JF - Allergy

IS - 12

ER -

EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

Keywords

Access to Document

Other files and links

Cite this